FY2024 EPS Estimates for Immunocore Raised by HC Wainwright

Immunocore Holdings plc (NASDAQ:IMCR) – Research analysts at HC Wainwright increased their FY2024 earnings per share estimates for shares of Immunocore in a report released on Thursday, November 7th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings per share of ($1.33) for the year, up from their prior forecast of ($2.14). HC Wainwright currently has a “Buy” rating and a $100.00 target price on the stock. The consensus estimate for Immunocore’s current full-year earnings is ($1.11) per share. HC Wainwright also issued estimates for Immunocore’s Q4 2024 earnings at ($0.78) EPS, Q1 2025 earnings at ($0.42) EPS, Q2 2025 earnings at ($0.48) EPS, Q3 2025 earnings at ($0.54) EPS, Q4 2025 earnings at ($0.96) EPS, FY2025 earnings at ($2.41) EPS, FY2026 earnings at ($2.34) EPS, FY2027 earnings at $1.04 EPS and FY2028 earnings at $4.21 EPS.

IMCR has been the topic of a number of other research reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Immunocore in a report on Monday, September 9th. Morgan Stanley lowered their price target on Immunocore from $80.00 to $74.00 and set an “overweight” rating on the stock in a report on Friday, October 11th. Guggenheim downgraded shares of Immunocore from a “buy” rating to a “neutral” rating in a report on Monday, October 7th. Mizuho downgraded shares of Immunocore from an “outperform” rating to a “neutral” rating and lowered their target price for the stock from $72.00 to $38.00 in a report on Monday. Finally, Oppenheimer reissued an “outperform” rating and issued a $89.00 target price (up previously from $87.00) on shares of Immunocore in a report on Friday, August 9th. One research analyst has rated the stock with a sell rating, three have given a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat, Immunocore has a consensus rating of “Moderate Buy” and a consensus target price of $69.18.

Immunocore Stock Performance

IMCR opened at $33.75 on Monday. The company has a current ratio of 3.78, a quick ratio of 5.15 and a debt-to-equity ratio of 1.03. The company has a market cap of $1.69 billion, a price-to-earnings ratio of -35.07 and a beta of 0.72. The company’s 50 day moving average is $32.61 and its 200 day moving average is $39.09. Immunocore has a 12-month low of $29.72 and a 12-month high of $76.98.

Immunocore (NASDAQ:IMCR) last announced its earnings results on Wednesday, November 6th. The company reported $0.17 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.50. Immunocore had a negative return on equity of 12.84% and a negative net margin of 15.87%. The business had revenue of $80.25 million for the quarter, compared to analysts’ expectations of $78.94 million. During the same period last year, the firm posted ($0.59) earnings per share. The business’s revenue for the quarter was up 23.7% on a year-over-year basis.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. SG Americas Securities LLC increased its position in Immunocore by 1,867.3% during the second quarter. SG Americas Securities LLC now owns 160,358 shares of the company’s stock valued at $5,435,000 after acquiring an additional 152,207 shares during the last quarter. Candriam S.C.A. boosted its stake in shares of Immunocore by 65.8% during the second quarter. Candriam S.C.A. now owns 313,423 shares of the company’s stock valued at $10,621,000 after purchasing an additional 124,417 shares during the period. Frazier Life Sciences Management L.P. purchased a new stake in shares of Immunocore during the second quarter valued at $3,686,000. Janus Henderson Group PLC boosted its stake in shares of Immunocore by 45.8% during the first quarter. Janus Henderson Group PLC now owns 257,080 shares of the company’s stock valued at $16,711,000 after purchasing an additional 80,748 shares during the period. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its stake in shares of Immunocore by 16.2% during the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 397,463 shares of the company’s stock valued at $13,470,000 after purchasing an additional 55,463 shares during the period. Institutional investors own 84.50% of the company’s stock.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.